SKB410 for Injection in Solid Tumors

Kelun Pharmaceutical

Status and phase

Active, not recruiting

Phase 1

Conditions

Advanced Solid Tumors

Treatments

Drug: SKB410 for injection

Study type

Interventional

Funder types

Industry

Identifiers

NCT05906537

SKB410-I-01

Details and patient eligibility

About

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.

Full description

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, PK profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.This is a dose escalation study , and subjects with advanced solid tumors will be enrolled to receive SKB410 for Injection.

Enrollment

54 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

At the time of signing the ICF: age ≥ 18 years, male or female.
Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumors who have failed/are intolerant/ineligible to or do not have standard therapy, and have at least one measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
Expected survival ≥ 3 months.
Subjects with adequate organ and bone marrow function confirmed by laboratory results within 3 days prior to the first dose.
Subjects of childbearing potential (male or female) must use effective medical contraception during the study and continue contraception until 210 days after the last dose for female subjects and until 120 days after the last dose for male subjects.
Ability to understand and willingness to sign ICF, and will be able to comply with the protocol-specified visits and relevant procedures.

Exclusion criteria

Has received anti-tumor therapy, including chemotherapy, targeted therapy, tumor immunotherapy, and traditional Chinese medicinal products with anti-tumor indications, within 4 weeks prior to the first dose or within 5 half-lives of known drugs (whichever is shorter).
Has received radiotherapy within 4 weeks prior to the first dose.
Has had major surgery within 4 weeks prior to the first dose.
Has received strong cytochrome P450 (CYP3A4) inhibitors or inducers (see Annex 4) within 2 weeks prior to the first dose or within 5 half-lives of known drug, whichever is longer.
Has not recovered to normal or ≤ Grade 1 from any AE and/or complication due to any prior therapy (except alopecia or pigmentation).
Has known history of allergy to any component of SKB410 or other monoclonal antibodies.
Has a known previous or concurrent other malignancies within 5 years prior to signing the ICF.
Presence of active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Has active autoimmune disease with systemic therapy or immunosuppressive therapy within 2 years prior to signing the ICF.
Has uncontrolled or severe cardiovascular disease.
Has uncontrolled systemic diseases.
Presence of clear neurological or psychiatric disorder.
Has active infection requiring systemic.
Has human immunodeficiency virus (HIV) infection; has any active viral hepatitis.
Pregnant or lactating.
Has prior autologous/allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
Has any other conditions such as medical history, treatment and laboratory abnormalities that may confound the study results, interfere with the subject's compliance, or impair the subject's interests, as assessed by the investigator or the sponsor.